Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
22 participants
INTERVENTIONAL
2019-04-08
2021-10-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does the use of Emdogain® in conjunction with crown lengthening surgery improve post-operative soft-tissue healing, decrease inflammation and reduce patient perception of pain compared to crown lengthening without addition of Emdogain®? The treatment group will receive Emdogain® during surgery, and the control group will undergo standard crown lengthening without Emdogain®.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gingival Recession Coverage With and Without Emdogain
NCT02230787
Influence of Enamel Matrix Derivative (Emdogain®) on Palate Wound Healing.
NCT03972267
Biologicals in Management of Intra-Bony Defects
NCT07292870
Evaluation of the Inflammatory and Healing Profile After Root Coverage With Emdogain®
NCT03059966
Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts
NCT01134081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Treatment/experimental group: patients undergoing surgical crown lengthening of a single site with application of PrefGel® + Emdogain®
* Control group: patients undergoing surgical crown lengthening of a single site with application of PrefGel® only
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Data was collected by a separate examiner who was also blinded to treatment allocation. Data analysis was carried out by an external statistician, minimizing the risk of bias.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment/experimental group
Patients undergoing surgical crown lengthening of a single site with application of PrefGel® + Emdogain®
PrefGel® + Emdogain®
Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
Control group
Patients undergoing surgical crown lengthening of a single site with application of PrefGel® only
PrefGel®
Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PrefGel® + Emdogain®
Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
PrefGel®
Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Were capable and willing to provide consent and complete treatment as well as follow-up appointments
* Were over the age of 18 years old
* Required surgical crown lengthening for functional reasons as outlined in background
* Had no contraindications to surgery (these include periodontal contraindications to crown lengthening such as poor crown-to-root ratio, furcation exposure or esthetic concerns)
Exclusion Criteria
* Pregnant women
* Women receiving estrogen therapy
* Patients who had received systemic antibiotics within the past 6 months
* Patients with severe systemic disease (ASA 3+) including: poorly controlled diabetes, blood dyscrasias, liver disease, immunosuppressive disorders, malignancy or who have had previous radiotherapy
* Patients with untreated, active periodontal disease
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Straumann AG
INDUSTRY
Amir Azarpazhooh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amir Azarpazhooh
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Howard Tenenbaum, Dr
Role: PRINCIPAL_INVESTIGATOR
University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Toronto, Faculty of Dentistry
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
37028
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.